RECENT PLACEMENT

Occam Places Kevin Coveney as CFO of Enveric Biosciences

Occam Places Kevin Coveney as CFO of Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, has added Kevin Coveney to its executive ranks. Kevin brings to Enveric three decades of accounting, finance, and operations experience, having previously served as Chief Financial Officer for multiple biotechnology companies.

Previously, Kevin was CFO of Memgen, Inc., a clinical-stage immune-oncology company focused on developing immunotherapies that can safely activate the immune system and be combined with other drugs to eradicate cancer. Prior to Memgen, Kevin was CFO of Q-State Biosciences, a biotech focused on CNS disorders.

Earlier in his career, Coveney also held senior positions at several global accounting firms, including Deloitte & Touche and Ernst & Young. Coveney earned his BS in management from the University of Massachusetts and served as a non-commissioned officer in the United States Coast Guard.

‍

Recent Placements

  1. John Reynders as Chief Data Sciences Officer of Neumora
  2. Jevan Soo Lenox as Chief People Officer at insitro
  3. Jorge Bartolome as CEO at Areteia Therapeutics
  4. Kevin Coveney as CFO of Enveric Biosciences
  5. Gurpreet Ratra as CBO at Skyline
About Occam Global

Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.